Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Nasal mucosal vaccine composition

一种疫苗组合物、鼻粘膜的技术，应用在药物组合、微生物、药物输送等方向，能够解决不明确、难以防御感染自身等问题

Inactive Publication Date: 2016-04-27
NITTO DENKO CORP
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Injectable vaccines have the problem of inducing an immune response (IgG antibody production) in the blood (systemic) without inducing an immune response (IgA antibody production) in the mucous membranes, although it can prevent the pathogens caused by infection. proliferates, but has difficulty defending itself from infection by pathogens due to the mucosal route
[0010] However, it is unclear whether the vaccine described in Patent Document 2 exhibits an effect when administered nasally using antigens other than influenza virus.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nasal mucosal vaccine composition
  • Nasal mucosal vaccine composition
  • Nasal mucosal vaccine composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1～5

[0072] (Examples 1-5, Comparative Examples 1-4)

[0073] Each administration group was manufactured with 10 parts.

[0074] A solution (1150 μg / mL) containing pneumococcal capsular polysaccharide (Pneumovax NP, manufactured by MSD Co., Ltd.) and lipopolysaccharide derived from Pantoea agglomerans (Natural Immunity Using the solution (50 mg / mL, manufactured by Giken Co., Ltd.), phosphate buffer solution (manufactured by NACALAITESQUE, INC.) was added to prepare 100 µL of a vaccine composition. For example, in Example 1, 8.7 μL of a solution containing pneumococcal capsular polysaccharide was added, 20 μL of a solution of lipopolysaccharide derived from Pantoea agglomerans (Pantoea agglomerans) was added, and then phosphate buffer was added to make the total amount 100 μL. Other Examples and Comparative Examples were also appropriately diluted to form a content equivalent to the dosage. In Comparative Example 4, only phosphate buffered saline (NACALAITESQUE, INC. .system).

...

Embodiment 6～10、 comparative example 5～7

[0081] Except that the solution containing pneumococcal capsular polysaccharide was changed to a solution containing HPV16 recombinant protein (HPV16, produced by PROSPEC Co., Ltd.) (820 μg / mL), basically based on Examples 1 to 5 and Comparative Examples 1 to 4, The procedure produced vaccine compositions corresponding to Table 2. For example, in Example 6, after adding 12.2 μL of the solution containing the HPV16 recombinant protein and 20 μL of the lipopolysaccharide solution derived from Pantoea agglomerans (Pantoea agglomerans), phosphate buffer was added so that the total amount was 100 μL.

[0082] Six mice (8-week-old female BALB / C mice, Japan SLC, Inc.) were anesthetized, and 10 μL of the prepared vaccine composition was nasally administered to each mouse. One week after the administration, the mice were anesthetized again, and 10 μL of the prepared vaccine composition was nasally administered to each mouse. After the second administration and one week later, the seru...

Embodiment 11～13、 comparative example 8

[0086] 50 μL of a solution containing attenuated surviving rotavirus (RotaTeq internal solution, manufactured by MSD Corporation) was added, and 50 μL of a solution of lipopolysaccharide (manufactured by NACALAITESQUE, INC.) derived from Pantoea agglomerans (Pantoea agglomerans) was added in Example 11 ( 2 mg / mL), in Example 12, 5 μL of lipopolysaccharide (NACALAITESQUE, INC.) solution derived from Pantoea agglomerans (Pantoea agglomerans) was added, and in Example 13, lipopolysaccharide derived from Pantoea agglomerans (Pantoea agglomerans) was added Polysaccharide (manufactured by NACALAITESQUE, INC.) solution 0.5 μL, 5 μL of glucopyranosyllipid (Glucopyranosyllipid) (MPLAs, manufactured by InvivoGen company) solution (2 mg / mL) was added in Comparative Example 8, phosphate buffer saline (NACALAITESQUE, INC. . system), thereby producing 100 μL of the vaccine composition. Six mice (8-week-old female BALB / C mice, Japan SLC, Inc.) were anesthetized, and 10 μL of the prepared vac...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The objective of the present invention is to provide a nasal mucosal vaccine composition that is safe, useful as a prevention or treatment agent for cancer or infectious disease, and can effectively induce a systemic immune response and a mucosal immune response. The nasal mucosal vaccine composition, which is administered to the nasal mucosa of humans or animals, is characterized by containing at least one type of antigen (but excluding influenza virus-derived antigens) and, as an immune activation agent, a lipopolysaccharide derived from at least one gram-negative bacteria selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter, or a salt thereof.

Description

technical field [0001] The present invention relates to a nasal mucosal vaccine composition useful as a preventive or therapeutic agent for infectious diseases and cancer. In particular, the present invention relates to a nasal mucosal vaccine composition capable of safely and effectively inducing systemic and mucosal immune responses by administering a specific lipopolysaccharide as an adjuvant to the nasal mucosa together with an antigen. Background technique [0002] As the dosage form of vaccine preparations, most of the commercialized preparations are now injections. Injectable vaccines have the problem of inducing an immune response (IgG antibody production) in the blood (systemic) without inducing an immune response (IgA antibody production) in the mucous membranes, although it can prevent the pathogens caused by infection. Proliferate, but it is difficult to defend against the infection itself of the pathogen due to the mucosal route. [0003] Therefore, in recent ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/02A61K39/12A61K39/39A61P31/04A61P35/00
CPCA61K39/00A61K2039/543A61K2039/55572A61K39/39A61P31/00A61P31/04A61P31/12A61P35/00A61P37/04A61P43/00A61K39/0011A61K9/0043A61K39/02A61K39/12A61K39/08A61K39/092A61K39/125A61K39/13A61K39/145A61K39/15A61K39/165A61K39/205A61K39/25A61K2039/5252A61K2039/5254A61K2039/575C12N2710/16734C12N2710/20034C12N2720/12334C12N2760/18434C12N2760/18734C12N2760/20134C12N2770/24134C12N2770/32434C12N2770/32634C12N2770/36234
Inventor 清远英司堀光彦大久保胜之浅利大介冈崎有道深坂昌弘松下恭平
Owner NITTO DENKO CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com